glp-1 kidney protection Glucagon-like peptide 1(GLP-1) receptor agonists in the management of the patient with type 2diabetes mellitus and chronic disease: an approach for the nephrologist GLP-1 mediated diuresis and natriuresis

Biochem Pharmacol 2020

Patients taking GLP-1 receptor agonists commonly report gastrointestinal side effects, including nausea, vomiting, diarrhoea, and constipation

Check if your employer offers GLP-1 coverage Corporate benefits packages increasingly include GLP-1 medication coverage

[16] GLP-1 endogenous in humans [16] glucagon endogenous in humans [16] oxyntomodulin amycretin/ zenagamtide UBT251 exendin-4 [16] [17] exenatide lixisenatide [16] albiglutide beinaglutide dulaglutide efpeglenatide langlenatide liraglutide [16] polyethylene glycol/PEG- loxenatide semaglutide taspoglutide ecnoglutide utreglutide glepaglutide apraglutide maridebart cafraglutide tirzepatide pegapamodutide mazdutide survodutide bamadutide pemvidutide cotadutide retatrutide Lithium chloride Cinchonine grutalumab dapiglutide DA1726 GX-G6 GZR18 HRS9531/ KAI-9531/ Ribupatide PB718 RAY1225 VCT220 VK2735 BLX7006 supaglutide/ efsubaglutide ASC30 HRS7535 Danuglipron Aleniglipron Lotiglipron Orforglipron (non peptide partial agonist) [18] Conveglipron Elecoglipron/ AZD 5004/ ECC 5004 CT-996 CT-388/ Enicepatide CT-868 HEC88473 HS-10535 UBT251 efinopegdutide efocipegtrutide Berobenatide NNC9204-1706 TG103 YP05002/YP-05002 Positive Negative Clinical significance [edit] GLP-1 receptor agonists are a class of medications that mimic the actions of the endogenous incretin hormone GLP-1, and are used in type 2 diabetes and obesity

In some users, this can lead to a decrease in dopamine, the brains feel good chemical

Liraglutide has anti-inflammatory and anti-amyloid properties in Streptozotocin-induced and 5xFAD mouse models of Alzheimers disease